Ayten Yazici
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayten Yazici has a total of 371 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Cefle
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye
43 shared publications - Duygu Temiz Karadag
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, İzmit, Turkey
25 shared publications - Ozlem Ozdemir Isik
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kocaeli University, Kocaeli, Turkey
20 shared publications - Neslihan Gokcen
Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Sakarya University, Sakarya, Türkiye
17 shared publications - Fatos Onen
Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Türkiye
10 shared publications - Servet Akar
Division of Rheumatology, Department of Internal Medicine, Izmir Katip Celebi University Faculty of Medicine, Izmir, Turkey
10 shared publications
Latest Publications
- 4 September 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (9) , 251
Lack of association between the Dudley Inflammatory Bowel Symptom Questionnaire and fecal calprotectin in axial spondyloarthritis: a cross-sectional study
- 4 September 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (9) , 251
Lack of association between the Dudley Inflammatory Bowel Symptom Questionnaire and fecal calprotectin in axial spondyloarthritis: a cross-sectional study
- 29 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 6103-6113
Longitudinal changes in renal function in rheumatoid arthritis patients treated with biologic agents: a retrospective cohort study
- 29 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 6103-6113
Longitudinal changes in renal function in rheumatoid arthritis patients treated with biologic agents: a retrospective cohort study
- Open Access
- 1 July 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002304
Longitudinal clinical course and long-term outcomes of SLE-associated interstitial lung disease
- 1 July 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002304
Open AccessLongitudinal clinical course and long-term outcomes of SLE-associated interstitial lung disease
- Open Access
- 15 June 2026
- Published by Caleo in Rheumatology Quarterly
- Vol. 4 (2) , 85-92
Age and Disease Duration Are Associated with Long-Term Retention of Certolizumab Pegol in Patients with Psoriatic Arthritis
Objective: Several factors such as effectiveness, safety, and compliance affect the drug survival in chronic disorders. Physicians consider long-term retention rates and reasons for discontinuation when selecting therapies. Identification of predictors of clinical response to certolizumab pegol (CZP) may aid the decision-making process for treating patients with psoriatic arthritis (PsA). The purpose of this study is to assess the drug survival of CZP in patients with PsA and to identify the predictors and reasons for discontinuation. Methods: Data on patient characteristics, demographics, diagnosis, disease duration, treatment, and outcomes have been collected since 2011 in Turkish Biologic (TURKBIO) Registry. By the end of December 2020, 68 PsA patients received CZP and were included. Kaplan–Meier analysis was used for drug survival analysis. Cox regression analysis was performed to evaluate the predictors associated with drug survival. Results: During a median follow-up of 47 months, 17 patients discontinued CZP treatment. At 36 months, the retention rate was 61.6%. Patients who discontinued CZP were older and had longer disease duration (P=.012 and P=.002, respectively). HLA-B27 positivity was associated with lower drug survival (P=.035). Biologic-naive patients demonstrated higher drug survival in Kaplan–Meier analysis (log-rank P=.02), although baseline comparison did not reach statistical significance (P = .062). In Cox regression analysis, age was identified as an independent predictor of treatment discontinuation (hazard ratio: 1.063, 95% CI: 1.019-1.109, P=.004). Conclusion: In this real-world analysis from the TURKBIO registry, CZP demonstrated moderate long-term drug retention in patients with PsA. Older age was independently associated with reduced treatment persistence, while longer disease duration was also associated with lower retention. Biologic-naive status was linked to improved drug survival. HLA-B27 positivity was also associated with lower drug survival; however, this finding should be interpreted with caution due to limited data availability. These results support the potential benefit of earlier initiation of CZP, particularly in biologic-naive patients, while highlighting the need for further studies to clarify the role of genetic factors in treatment persistence.
- 15 June 2026
- Published by Caleo in Rheumatology Quarterly
- Vol. 4 (2) , 85-92
Open AccessAge and Disease Duration Are Associated with Long-Term Retention of Certolizumab Pegol in Patients with Psoriatic Arthritis
Objective: Several factors such as effectiveness, safety, and compliance affect the drug survival in chronic disorders. Physicians consider long-term retention rates and reasons for discontinuation when selecting therapies. Identification of predictors of clinical response to certolizumab pegol (CZP) may aid the decision-making process for treating patients with psoriatic arthritis (PsA). The purpose of this study is to assess the drug survival of CZP in patients with PsA and to identify the predictors and reasons for discontinuation. Methods: Data on patient characteristics, demographics, diagnosis, disease duration, treatment, and outcomes have been collected since 2011 in Turkish Biologic (TURKBIO) Registry. By the end of December 2020, 68 PsA patients received CZP and were included. Kaplan–Meier analysis was used for drug survival analysis. Cox regression analysis was performed to evaluate the predictors associated with drug survival. Results: During a median follow-up of 47 months, 17 patients discontinued CZP treatment. At 36 months, the retention rate was 61.6%. Patients who discontinued CZP were older and had longer disease duration (P=.012 and P=.002, respectively). HLA-B27 positivity was associated with lower drug survival (P=.035). Biologic-naive patients demonstrated higher drug survival in Kaplan–Meier analysis (log-rank P=.02), although baseline comparison did not reach statistical significance (P = .062). In Cox regression analysis, age was identified as an independent predictor of treatment discontinuation (hazard ratio: 1.063, 95% CI: 1.019-1.109, P=.004). Conclusion: In this real-world analysis from the TURKBIO registry, CZP demonstrated moderate long-term drug retention in patients with PsA. Older age was independently associated with reduced treatment persistence, while longer disease duration was also associated with lower retention. Biologic-naive status was linked to improved drug survival. HLA-B27 positivity was also associated with lower drug survival; however, this finding should be interpreted with caution due to limited data availability. These results support the potential benefit of earlier initiation of CZP, particularly in biologic-naive patients, while highlighting the need for further studies to clarify the role of genetic factors in treatment persistence.
- 8 June 2026
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 9, 1-5
INITIAL MRI FINDINGS IN DIFFERENT INFLAMMATORY SPONDYLOARTHROPATHY SUBTYPES: A TOPOGRAPHIC ANALYSIS OF SACROILIAC JOINT INVOLVEMENT
Objective: We aimed to investigate whether different inflammatory spondyloarthropathy (ISPA) subtypes demonstrate distinct topographic patterns of sacroiliac joint involvement on their initial MRI examinations. Methods: Initial MRI studies of 126 patients with clinically confirmed ISPA were retrospectively evaluated. Bone marrow edema (BME) was classified as an acute finding, while subchondral sclerosis, erosions, fatty infiltration, and ankylosis were classified as chronic changes. All findings were documented according to their location in the upper, middle, and lower thirds of the joint, as well as involvement of the ligamentous versus synovial portions and sacral versus iliac dominance. Results: The study included 62 patients with ankylosing spondylitis (AS), 19 with psoriatic spondyloarthritis (PSA), 17 with undifferentiated spondyloarthritis (USPA), 14 with enteropathic spondyloarthritis (ESPA), and 14 with other inflammatory conditions. On initial MRI, BME was most frequently observed in the middle third (68%) and lower third (52%) of the joints. PSA showed significantly more frequent lower third involvement (80% vs 41–58% in other subtypes, p=0.024). AS demonstrated sacral-dominant BME (44% vs 9–40%, p=0.013), while ESPA showed iliac-dominant involvement (66% vs 16–26%, p=0.003). PSA exhibited a symmetrical pattern more frequently (60% vs 23–50%, p=0.043). No significant differences were observed among subtypes regarding chronic structural changes. Conclusion: Different ISPA subtypes demonstrate distinct topographic patterns of sacroiliac joint involvement on initial MRI, which may aid in early differential diagnosis.
- 8 June 2026
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 9, 1-5
INITIAL MRI FINDINGS IN DIFFERENT INFLAMMATORY SPONDYLOARTHROPATHY SUBTYPES: A TOPOGRAPHIC ANALYSIS OF SACROILIAC JOINT INVOLVEMENT
Objective: We aimed to investigate whether different inflammatory spondyloarthropathy (ISPA) subtypes demonstrate distinct topographic patterns of sacroiliac joint involvement on their initial MRI examinations. Methods: Initial MRI studies of 126 patients with clinically confirmed ISPA were retrospectively evaluated. Bone marrow edema (BME) was classified as an acute finding, while subchondral sclerosis, erosions, fatty infiltration, and ankylosis were classified as chronic changes. All findings were documented according to their location in the upper, middle, and lower thirds of the joint, as well as involvement of the ligamentous versus synovial portions and sacral versus iliac dominance. Results: The study included 62 patients with ankylosing spondylitis (AS), 19 with psoriatic spondyloarthritis (PSA), 17 with undifferentiated spondyloarthritis (USPA), 14 with enteropathic spondyloarthritis (ESPA), and 14 with other inflammatory conditions. On initial MRI, BME was most frequently observed in the middle third (68%) and lower third (52%) of the joints. PSA showed significantly more frequent lower third involvement (80% vs 41–58% in other subtypes, p=0.024). AS demonstrated sacral-dominant BME (44% vs 9–40%, p=0.013), while ESPA showed iliac-dominant involvement (66% vs 16–26%, p=0.003). PSA exhibited a symmetrical pattern more frequently (60% vs 23–50%, p=0.043). No significant differences were observed among subtypes regarding chronic structural changes. Conclusion: Different ISPA subtypes demonstrate distinct topographic patterns of sacroiliac joint involvement on initial MRI, which may aid in early differential diagnosis.
- 8 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (6) , e70724
Outcomes of Vascular Interventions in Takayasu Arteritis and the Role of Biologic Therapy: A Multicenter Retrospective Study
Objectives: Takayasu arteritis (TAK) may lead to arterial stenosis/occlusion and aneurysms, occasionally requiring vascular interventions. We evaluated outcomes, restenosis, and complications after vascular interventions in TAK and explored factors associated with restenosis. Methods: We retrospectively included TAK patients who underwent extracardiac endovascular or surgical vascular interventions before or after TAK diagnosis across eight tertiary centers (1995–2024). Indications, disease activity status at the time of intervention, procedural characteristics, early/late outcomes, major complications, and restenosis were recorded. Restenosis was defined as > 70% stenosis on follow‐up imaging performed ≥ 3 months after the procedure. Restenosis analyses were restricted to steno‐occlusive lesions. Results: We included 119 patients with 201 treated lesions (185 steno‐occlusive lesions; 16 aneurysms/dissections). Of all procedures, 61.2% ( n = 123) were performed after TAK diagnosis under immunosuppressive therapy. Follow‐up imaging was available for 170/185 steno‐occlusive procedures, and restenosis status was evaluable in 168 procedures; restenosis occurred in 82/168 (48.8%) with a median time to restenosis of 19.5 months. In exploratory Kaplan–Meier analysis, 1‐, 3‐, and 5‐year restenosis‐free patency rates were 76.8%, 63.6%, and 56.5%, respectively. In analyses restricted to post‐diagnosis steno‐occlusive procedures, crude restenosis was significantly less frequent under biologic therapy than without biologic therapy (30.8% vs. 53.1%; Fisher's exact p = 0.040); however, biologic therapy was not associated with time to restenosis in Cox regression (HR 1.01, 95% CI 0.51–1.99; p = 0.97) or patient‐clustered Cox analysis (HR 1.01, 95% CI 0.47–2.18; p = 0.98). Major complication rates were 3.9% for endovascular procedures and 12.5% for surgical procedures. Overall mortality was 11.8%, with two deaths attributed to procedure‐related complications. Conclusions: Vascular interventions in selected patients with Takayasu arteritis were associated with acceptable major complication rates. Among post‐diagnosis steno‐occlusive procedures, biologic therapy was associated with lower restenosis rates in crude analyses; however, this association was not sustained after accounting for restenosis timing. Therefore, the potential role of biologic therapy in improving post‐interventional vascular outcomes should be interpreted cautiously and requires confirmation in prospective studies with standardized imaging surveillance.
- 8 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (6) , e70724
Outcomes of Vascular Interventions in Takayasu Arteritis and the Role of Biologic Therapy: A Multicenter Retrospective Study
Objectives: Takayasu arteritis (TAK) may lead to arterial stenosis/occlusion and aneurysms, occasionally requiring vascular interventions. We evaluated outcomes, restenosis, and complications after vascular interventions in TAK and explored factors associated with restenosis. Methods: We retrospectively included TAK patients who underwent extracardiac endovascular or surgical vascular interventions before or after TAK diagnosis across eight tertiary centers (1995–2024). Indications, disease activity status at the time of intervention, procedural characteristics, early/late outcomes, major complications, and restenosis were recorded. Restenosis was defined as > 70% stenosis on follow‐up imaging performed ≥ 3 months after the procedure. Restenosis analyses were restricted to steno‐occlusive lesions. Results: We included 119 patients with 201 treated lesions (185 steno‐occlusive lesions; 16 aneurysms/dissections). Of all procedures, 61.2% ( n = 123) were performed after TAK diagnosis under immunosuppressive therapy. Follow‐up imaging was available for 170/185 steno‐occlusive procedures, and restenosis status was evaluable in 168 procedures; restenosis occurred in 82/168 (48.8%) with a median time to restenosis of 19.5 months. In exploratory Kaplan–Meier analysis, 1‐, 3‐, and 5‐year restenosis‐free patency rates were 76.8%, 63.6%, and 56.5%, respectively. In analyses restricted to post‐diagnosis steno‐occlusive procedures, crude restenosis was significantly less frequent under biologic therapy than without biologic therapy (30.8% vs. 53.1%; Fisher's exact p = 0.040); however, biologic therapy was not associated with time to restenosis in Cox regression (HR 1.01, 95% CI 0.51–1.99; p = 0.97) or patient‐clustered Cox analysis (HR 1.01, 95% CI 0.47–2.18; p = 0.98). Major complication rates were 3.9% for endovascular procedures and 12.5% for surgical procedures. Overall mortality was 11.8%, with two deaths attributed to procedure‐related complications. Conclusions: Vascular interventions in selected patients with Takayasu arteritis were associated with acceptable major complication rates. Among post‐diagnosis steno‐occlusive procedures, biologic therapy was associated with lower restenosis rates in crude analyses; however, this association was not sustained after accounting for restenosis timing. Therefore, the potential role of biologic therapy in improving post‐interventional vascular outcomes should be interpreted cautiously and requires confirmation in prospective studies with standardized imaging surveillance.
- 22 May 2026
- Published by Caleo in Rheumatology Quarterly
SEROPREVALENCE AND ANTIBODY TITERS FOLLOWING COVID-19 INFECTION IN RHEUMATIC DISEASE PATIENTS: A COMPARATIVE CROSS-SECTIONAL STUDY
Objection: Data on the clinical course of COVID-19 and subsequent humoral immune responses in patients with rheumatic diseases remain limited. This study aimed to compare SARS-CoV-2 antibody responses between patients with rheumatic diseases and healthy controls and to identify clinical and treatment-related factors associated with antibody levels. Methods: This prospectively designed, single-center cross-sectional study included unvaccinated adults with rheumatoid arthritis, systemic lupus erythematosus, or ankylosing spondylitis who had a previous COVID-19 infection, along with age- and sex-matched healthy controls. COVID-19 was identified by PCR confirmation or compatible thoracic CT findings, and anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies were assessed 1-6 months after infection using Elecsys immunoassays. Results: PCR-confirmed infection (P< .001) and several COVID-19-related symptoms, including headache, dyspnea, nausea/vomiting, fatigue, sore throat, and arthralgia, were significantly more frequent in the patient group (all P < .05). However, hospitalization and pulmonary involvement were each significantly more common in the control group (both P< .001). Intensive care admission was similarly low in both groups. Anti-S seropositivity was significantly higher in patients than in controls (P < .001), while anti-N seropositivity and anti-N/anti-S antibody titers were comparable between groups. Antibody levels did not differ significantly among rheumatic disease subgroups. However, both anti-N and anti-S titers were significantly higher in patients not receiving biologic therapy (both P < .001). Conclusion: Humoral immune responses following COVID-19 appeared to be largely preserved in patients with rheumatic diseases. Although anti-S seropositivity was higher in the patient group, antibody titers were lower among those receiving biologic therapy, suggesting a potential treatment-related effect on humoral immunity. Larger studies are warranted to confirm these findings.
- 22 May 2026
- Published by Caleo in Rheumatology Quarterly
SEROPREVALENCE AND ANTIBODY TITERS FOLLOWING COVID-19 INFECTION IN RHEUMATIC DISEASE PATIENTS: A COMPARATIVE CROSS-SECTIONAL STUDY
Objection: Data on the clinical course of COVID-19 and subsequent humoral immune responses in patients with rheumatic diseases remain limited. This study aimed to compare SARS-CoV-2 antibody responses between patients with rheumatic diseases and healthy controls and to identify clinical and treatment-related factors associated with antibody levels. Methods: This prospectively designed, single-center cross-sectional study included unvaccinated adults with rheumatoid arthritis, systemic lupus erythematosus, or ankylosing spondylitis who had a previous COVID-19 infection, along with age- and sex-matched healthy controls. COVID-19 was identified by PCR confirmation or compatible thoracic CT findings, and anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies were assessed 1-6 months after infection using Elecsys immunoassays. Results: PCR-confirmed infection (P< .001) and several COVID-19-related symptoms, including headache, dyspnea, nausea/vomiting, fatigue, sore throat, and arthralgia, were significantly more frequent in the patient group (all P < .05). However, hospitalization and pulmonary involvement were each significantly more common in the control group (both P< .001). Intensive care admission was similarly low in both groups. Anti-S seropositivity was significantly higher in patients than in controls (P < .001), while anti-N seropositivity and anti-N/anti-S antibody titers were comparable between groups. Antibody levels did not differ significantly among rheumatic disease subgroups. However, both anti-N and anti-S titers were significantly higher in patients not receiving biologic therapy (both P < .001). Conclusion: Humoral immune responses following COVID-19 appeared to be largely preserved in patients with rheumatic diseases. Although anti-S seropositivity was higher in the patient group, antibody titers were lower among those receiving biologic therapy, suggesting a potential treatment-related effect on humoral immunity. Larger studies are warranted to confirm these findings.
- 24 April 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (5) , e70665
Case Report: Atypical Presentation of Nivolumab‐Induced Immune‐Related Vasculopathy Imitating Raynaud's Phenomenon in Lung Cancer
- 24 April 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (5) , e70665
Case Report: Atypical Presentation of Nivolumab‐Induced Immune‐Related Vasculopathy Imitating Raynaud's Phenomenon in Lung Cancer
- Open Access
- 9 April 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (4) , 76
Validation of the Dudley inflammatory bowel symptom questionnaire for assessing gastrointestinal symptom burden in axial spondyloarthritis
Subclinical and overt inflammatory bowel disease (IBD) is frequently observed in patients with axial spondyloarthritis (ax-SpA), traditionally identified through invasive ileocolonoscopic evaluation. Validated non-invasive assessing instruments are therefore needed to facilitate early detection. This study aimed to validate the Turkish version of the Dudley Inflammatory Bowel Symptom Questionnaire (DISQ) as a tool for assessing gastrointestinal symptom burden suggestive of intestinal involvement in patients with axial spondyloarthritis. In this cross-sectional validation study, 174 patients fulfilling the 2009 Assessment of SpondyloArthritis international Society (ASAS) criteria for axial SpA were enrolled. Convergent validity was assessed by examining correlations between DISQ scores and disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), functional status (Bath Ankylosing Spondylitis Functional Index [BASFI]), and health-related quality of life (Short Form-36 [SF-36]). Discriminant validity was evaluated by comparing DISQ scores in patients with and without gastrointestinal symptoms suggestive of IBD. Test–retest reliability was assessed by re-administration of the DISQ after one month. Internal consistency was evaluated using Cronbach’s alpha. DISQ scores demonstrated moderate positive correlations with BASDAI (r = 0.432, p < 0.001) and BASFI (r = 0.248, p = 0.001), and a strong inverse correlation with SF-36 scores (p < 0.001), supporting convergent validity. Patients reporting diarrhea, abdominal pain, oral aphthae, or mucus in stool had significantly higher DISQ scores than those without these symptoms (all p ≤ 0.008), confirming discriminant validity. The Turkish version of the DISQ demonstrated acceptable internal consistency (Cronbach’s α = 0.70) and good test–retest reliability (ICC = 0.76; 95% CI: 0.51–0.82; p < 0.001). The Turkish version of DISQ demonstrates satisfactory validity and reliability as a non-invasive assessment instrument for gastrointestinal symptoms suggestive of bowel inflammation in patients with ax-SpA. Future studies incorporating endoscopic and biomarker-based outcomes are warranted to define clinically meaningful cut-off values and determine its role in routine clinical practice.
- 9 April 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (4) , 76
Open AccessValidation of the Dudley inflammatory bowel symptom questionnaire for assessing gastrointestinal symptom burden in axial spondyloarthritis
Subclinical and overt inflammatory bowel disease (IBD) is frequently observed in patients with axial spondyloarthritis (ax-SpA), traditionally identified through invasive ileocolonoscopic evaluation. Validated non-invasive assessing instruments are therefore needed to facilitate early detection. This study aimed to validate the Turkish version of the Dudley Inflammatory Bowel Symptom Questionnaire (DISQ) as a tool for assessing gastrointestinal symptom burden suggestive of intestinal involvement in patients with axial spondyloarthritis. In this cross-sectional validation study, 174 patients fulfilling the 2009 Assessment of SpondyloArthritis international Society (ASAS) criteria for axial SpA were enrolled. Convergent validity was assessed by examining correlations between DISQ scores and disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), functional status (Bath Ankylosing Spondylitis Functional Index [BASFI]), and health-related quality of life (Short Form-36 [SF-36]). Discriminant validity was evaluated by comparing DISQ scores in patients with and without gastrointestinal symptoms suggestive of IBD. Test–retest reliability was assessed by re-administration of the DISQ after one month. Internal consistency was evaluated using Cronbach’s alpha. DISQ scores demonstrated moderate positive correlations with BASDAI (r = 0.432, p < 0.001) and BASFI (r = 0.248, p = 0.001), and a strong inverse correlation with SF-36 scores (p < 0.001), supporting convergent validity. Patients reporting diarrhea, abdominal pain, oral aphthae, or mucus in stool had significantly higher DISQ scores than those without these symptoms (all p ≤ 0.008), confirming discriminant validity. The Turkish version of the DISQ demonstrated acceptable internal consistency (Cronbach’s α = 0.70) and good test–retest reliability (ICC = 0.76; 95% CI: 0.51–0.82; p < 0.001). The Turkish version of DISQ demonstrates satisfactory validity and reliability as a non-invasive assessment instrument for gastrointestinal symptoms suggestive of bowel inflammation in patients with ax-SpA. Future studies incorporating endoscopic and biomarker-based outcomes are warranted to define clinically meaningful cut-off values and determine its role in routine clinical practice.
- Open Access
- 7 April 2026
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (5) , 1647-1654
Screening of osteoporosis in patients with ANCA-associated vasculitis (AAV) is quite low: results from a country-wide study
Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.
- 7 April 2026
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (5) , 1647-1654
Open AccessScreening of osteoporosis in patients with ANCA-associated vasculitis (AAV) is quite low: results from a country-wide study
Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.